Evidence map›Paper›PMID 26314990›Full record

ArticleAnnals of biomedical engineering2016

Sustained Efficacy and Arterial Drug Retention by a Fast Drug Eluting Cross-Linked Fatty Acid Coronary Stent Coating.

Natalie Artzi, Abraham R Tzafriri, Keith M Faucher, Geoffrey Moodie, Theresa Albergo, Suzanne Conroy, Scott Corbeil, Paul Martakos, Renu Virmani, Elazer R Edelman

Abstract read
In one paragraph

Article in Annals of biomedical engineering, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Endovascular Drug Delivery.Life (Basel, Switzerland) · 2024
    Review
  3. Evolution of drug-eluting biomedical implants for sustained drug delivery.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2021
    Review
  4. Article
  5. Taking paclitaxel coated balloons to a higher level: Predicting coating dissolution kinetics, tissue retention and dosing dynamics.Journal of controlled release : official journal of the Controlled Release Society · 2019
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Natalie ArtziInstitute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA.
Abraham R TzafririInstitute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA. ramitz@mit.edu.
Keith M FaucherMAQUET Vascular Systems (Formerly Atrium Medical Corporation), 40 Continental Blvd., Merrimack, NH, 03054, USA.
Geoffrey MoodieMAQUET Vascular Systems (Formerly Atrium Medical Corporation), 40 Continental Blvd., Merrimack, NH, 03054, USA.
Theresa AlbergoMAQUET Vascular Systems (Formerly Atrium Medical Corporation), 40 Continental Blvd., Merrimack, NH, 03054, USA.
Suzanne ConroyMAQUET Vascular Systems (Formerly Atrium Medical Corporation), 40 Continental Blvd., Merrimack, NH, 03054, USA.
Scott CorbeilMAQUET Vascular Systems (Formerly Atrium Medical Corporation), 40 Continental Blvd., Merrimack, NH, 03054, USA.
Paul MartakosMAQUET Vascular Systems (Formerly Atrium Medical Corporation), 40 Continental Blvd., Merrimack, NH, 03054, USA.
Renu VirmaniCV Path Institute, 19 Firstfield Road, Gaithersburg, MD, 20878, USA.
Elazer R EdelmanInstitute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA.

Funding

Vascular Drug Delivery - Supplement for EquipmentR01GM049039 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI EDELMAN, ELAZER R · 1994 to 2019
$8.9M
NIGMS NIH HHS R01 GM049039NIGMS NIH HHS R01 GM-49039
6 · The paper itself

Abstract

The long held assumption that sustained drug elution from stent coatings over weeks to months is imperative for clinical efficacy has limited the choice for stent coating materials. We developed and evaluated an omega-3 fatty acid (O3FA) based stent coating that is 85% absorbed and elutes 97% of its Sirolimus analog (Corolimus) load within 8d of implantation. O3FA coated stents sustained drug levels in porcine coronary arteries similarly to those achieved by slow-eluting durable coated Cypher Select Plus Stents and with significantly lower levels of granuloma formation and luminal stenosis. Computational modeling confirmed that diffusion and binding constants of Corolimus and Sirolimus are identical and explained that the sustained retention of Corolimus was facilitated by binding to high affinity intracellular receptors (FKBP12). First in man outcomes were positive-unlike Cypher stents where late lumen loss drops over 6 month, there was a stable effect without diminution in the presence of O3FA. These results speak to a new paradigm whereby the safety of drug eluting stents can be optimized through the use of resorbable biocompatible coating materials with resorption kinetics that coincide with the dissociation and tissue elimination of receptor-bound drug.

Indexed as

Coated Materials, BiocompatibleFatty Acids, Omega-3Materials TestingModels, CardiovascularSirolimusAnimalsMaleRabbitsSwineCoated Materials, BiocompatibleFatty Acids, Omega-3SirolimusComputational modelingDrug eluting stentsSirolimus analogs

Identifiers

PMID26314990
PMCPMC4767594

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.